Senior Director, Assay Services
March 10, 2026
Job Title: Sr. Director, Assay Services
Job Description
SeromYx is an assay services company enabling the discovery and development of safer and more effective vaccines and antibody therapeutics by our clients through antibody effector function profiling. Our technology platform combines biophysical and functional assays with machine learning, to understand how vaccines and antibodies interact with the immune system and to help predict therapeutic and clinical outcomes. Our work involves design and delivery of complex assay services, conducted under Good Clinical Lab Practice (GCLP), for biopharma, NGO, and governmental clients.
As we scale our organization for further growth, we are looking for an experienced and motivated Sr. Director, Assay Services who will help ensure that SeromYx achieves its business goals and delights its customers. Reporting to the CEO, this role will play a critical leadership role in managing and optimizing the efficiency, profitability, and scalability of our service business.
This position spans team management, client management and project management to ensure that laboratory projects, client contracts, resource utilization, and team development progress in support of the company’s growth. The ideal candidate is experienced at managing and coaching high-performing teams in a fast-paced, customer-centric environment, has strong bioanalytical assay experience, business acumen, and the ability to manage multiple high complexity projects simultaneously in an assay services organization.
Key Responsibilities
- Effectively lead scientific team
- Manage and mentor an experienced scientific team comprising Analytical Project
- Managers, laboratory scientists and computational biologists to achieve project goals.
- Promote a culture of performance, collaboration, and continuous improvement within the organization.
- Deeply understand project and laboratory workflows and propose and support efforts to enhance processes and systems.
- Manage individual development and performance goals and provide regular, ongoing, actionable feedback.
- Drive project delivery
- Design and deliver assay service projects on time and on budget.
- Manage, report on, and continuously improve revenue achievement, milestone tracking, on time delivery, resource allocation, project scheduling, capacity planning, and workflow optimization.
- Support drafting and coordination of Statements of Work (SOWs) and Study Reports.
- Drive business growth through client relationships and commercial focus
- Manage and cultivate relationships with clients so as to delight customers and earn repeat business.
- Contribute to winning new contracts by providing / coordinating technical commercial support.
- Support pricing strategy development, proposal review, and contract negotiation.
- Support identification of and outreach to new prospective clients and funding sources.
- Build and maintain positive, proactive and collaborative relationships across the Company.
Examples:
- Partner with VP, Research to ensure study plans and study reports meet highest scientific standards and to develop and refine technical delivery processes, and platform enhancements.
- Partner with CEO/CFO/Commercial/Operations to develop and manage budgets, pricing models, forecasts, and revenue reporting.
- Partner with Operations and QA to meet and enhance quality deliverables and ensure
- GCLP compliance requirements are met.
Skills
- Successful team leadership and team-building capabilities within an assay services business.
- Client management skills in winning/retaining business in an emerging technology area
- Direct experience with developing, implementing, and optimizing multiplex immunoassays, cellbased assays and biophysical assays – flow cytometry, Luminex, SPR assay experience preferred
- Strong understanding of laboratory workflows, quality systems, and regulatory environments (e.g. GCLP, GLP, ISO)
- Exceptional analytical, organizational, and communication skills
- Proficiency with business and project management tools (e.g. CRM, LIMS, Excel, Gantt charts).
- Experience with budgeting, pricing, and revenue reporting
- Familiarity with reporting requirements for US Government funding agencies highly desirable.
- Thrives in a high growth small company environment
Qualifications
- >5 years of progressive experience in technical and/or assay service operations, preferably within a CRO, CDMO or similar organization.
- >5 years experience managing and developing high performing scientific teams
- Demonstrated experience in successfully managing, delivering and completing technical and commercial projects.
- Experience developing and managing budgets, operational metrics, statements of work and client communications.
- Knowledge of therapeutic discovery and development workflows.
- Familiarity with antibody effector functions and Fc engineering is desirable.
- Master’s degree (Ph.D. preferred) in biology, immunology or related field.
Email resumes to: jobs@seromyx.com
The Fc Review: How do antibody structure and binding dynamics shape ADCC signaling? A recent study in The AAPS Journal explores how multiple antibody design features, including Fab affinity, hinge flexibility, Fc engagement, and antigen density, influence antibody-dependent cellular cytotoxicity (ADCC) signaling. Background: ADCC is a key mechanism of action for many therapeutic antibodies, yet the strength of this response depends on more than Fcγ receptor binding alone. Productive immune activation requires antibodies to bridge target cells and effector cells within the immune synapse, forming receptor crosslinks that trigger downstream signaling. Using a combination of computational modeling and experimental data, this study examines how structural properties of antibodies influence these crosslinking events and ultimately shape ADCC signaling outcomes. The study highlights: ADCC signaling is influenced by multiple antibody properties, including Fab affinity, hinge flexibility, Fc receptor engagement, and antigen expression levels. Antibody structure affects how efficiently Fc receptors and target antigens are crosslinked within the immune synapse. In some cases, moderate Fab affinity supported stronger signaling by favoring productive crosslinking configurations. Antibody valency and hinge flexibility also influenced signaling outcomes by altering the geometry of immune synapse interactions.
The Fc Review: How well do our preclinical models capture human Fc biology? A new Science Immunology study takes a deep look at Fcγ receptor and FcRn expression across humans, non-human primates, and mice, highlighting how species-specific differences shape Fc-mediated immune function. Background: Fc-dependent activity is influenced not only by antibody design, but also by where and how Fcγ receptors are expressed across immune cell types and tissues. While animal models remain central to #antibody development, differences in Fcγ receptor biology across species can complicate interpretation of Fc-driven mechanisms. The study highlights: Species-specific differences in Fcγ receptor expression patterns across immune cell subsets and tissues. Context-dependent regulation of Fcγ receptors by inflammatory cues, with expression shifting across cell types and environments. These differences influence how Fc-mediated functions are engaged and interpreted across experimental systems. Cross-species variation in FcγR and FcRn biology helps explain why Fc-dependent effects observed preclinically may not always translate cleanly to human settings.
The Fc Review: How are antibody developers actually using Fc engineering today? A recent analysis of the IMGT/mAb-DB database takes a systematic look at engineered Fc variants across therapeutic antibodies and fusion proteins, offering a real-world snapshot of how Fc design choices are being deployed in the clinic. Background: Fc engineering is often discussed in terms of individual mutations or isolated use cases. But at an industry level, it’s less clear how frequently Fc variants are used, which functions are prioritized, and whether antibodies rely on single or multiple Fc modifications. By mining curated entries in IMGT/mAb-DB, this study steps back to examine Fc engineering trends across approved and clinical-stage molecules. The review highlights: Fc engineering is widespread across therapeutic antibodies and fusion proteins cataloged in IMGT/mAb-DB Effector silencing strategies are commonly employed, particularly in programs prioritizing safety and controlled immune engagement Many molecules incorporate multiple Fc variants, rather than a single engineered change Fc modifications are used across a range of mechanisms and formats, underscoring Fc’s role as an intentional design lever
World Vaccine Congress US 2026
The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. Can we program the Fc region? A recent bioRxiv preprint explores this question at scale, using millions of Fc variants to train machine learning models that predict functional outcomes across FcγR interactions. Background: Through engagement with Fc-receptors, the antibody Fc domain can direct a broad range of immune activities, including phagocytosis, cytokine release, antigen presentation, and immune cell polarization – each of which could be precisely tuned to combat disease. Fc engineering has traditionally focused on modifying one property at a time (E.g., ADCC, ADCP, or half-life). This work instead treats the Fc region as a functional design space and explores how sequence variations across the Fc domain can be linked to real immune engagement.
The Fc Review: One Fc variant, three advantages? A Nature Communications study demonstrates how a single Fc-engineered IgG achieved improved half-life, mucosal distribution, and enhanced immune-mediated killing, across both cancer and bacterial models. Background: Fc engineering is often discussed through a single lens, half-life extension, effector boosting, or silencing. This paper explores a broader question: can an Fc variant containing three point mutations deliver multiple functional gains across different biological systems?
The Fc Review: How does Fc engineering shape bispecific antibody function? A Frontiers in Bioengineering and Biotechnology review explores how the Fc region can be tuned to control effector function, half-life, and safety, key levers in the design of next-generation bispecific antibodies ( bsAbs ). Background: Bispecific antibodies bring new therapeutic possibilities by engaging multiple targets at once. But this complexity also brings new challenges, from unwanted immune activation to altered pharmacokinetics . The Fc region plays a central role here, acting as both a stabilizing scaffold and a regulator of immune effector engagement
Abstract: Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding FcγR expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune-engaging antibody design and patient stratification. In this study, we investigated FcR-expressing immune effector cells in HER2 + and triple-negative breast cancers (TNBC), including neoadjuvant chemotherapy–resistant disease. FcγRIIIa expression, FcγRIIIa + NK cells, and classically activated (M1-like) macrophages correlated with improved anti-HER2 antibody efficacy. FcγRIIIa protein and FcγRIIIa + NK cells and macrophages were present in primary TNBC and retained in treatment-resistant tumors.
Background Authorized COVID-19 vaccines require boosters for continued protection; however, the lack of crossplatform compatible boosters creates practical challenges to keeping populations protected. Methods This Phase 3, multicenter, international, randomized, active-controlled trial compared UB-612 as a thirddose heterologous booster to BNT162b2, ChAdOx1-S, or BBIBP-CorV homologous boosters in healthy subjects aged ≥16 years. Participants were randomly assigned 1:1 to receive a single intramuscular injection of UB-612 or an active comparator matching the primary dose, and were stratified for age, sex, N-protein seropositivity, and time since the last dose of their primary series COVID-19 vaccination. The primary objective was to show noninferiority of neutralizing antibody geometric mean titer (GMT) against live SARS-CoV-2 Wuhan strain after boosting with UB-612 or each of the licensed platform vaccines. Secondary and exploratory objectives covered short and long-term antibody responses. The safety analysis addressed subject and investigator reported adverse events. The study was registered on ClinicalTrials.gov, NCT05293665, and completed on September 12, 2023.
The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. How does Fc engineering shape the translation of antibodies from preclinical models to the clinic? A new industry-wide review with 15 case studies examines the impact of Fc modifications on pharmacology and safety, and the challenges of predicting human outcomes from nonclinical studies. Background: Fc regions do not only extend half-life, they drive functions like ADCC , ADCP, CDC, and immune modulation. Engineering the Fc can enhance, silence, or redirect these activities. But the same changes that deliver potency can also introduce risk, especially when preclinical models do not fully mirror human Fc receptor biology.
